Udvalget besluttede, at fordelene ved Suboxone som substitutionsbehandling for opioidafhængighed er større end risiciene, og udvalget anbefalede, at Suboxone fik markedsføringstilladelse.
They decided that Suboxone’ s benefits as a substitution treatment for opioid drug dependency are greater than its risks and they recommended that Suboxone be given marketing authorisation.